Isaac B Rhea1, Alexander R Lyon2, Michael G Fradley3. 1. Cardio-Oncology Program, Division of Cardiovascular Medicine, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine, 12902 USF Magnolia Dr., MCB-CPT, Tampa, FL, 33612-9416, USA. 2. Cardio-Oncology Service, London UK and National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital, London, UK. 3. Cardio-Oncology Program, Division of Cardiovascular Medicine, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine, 12902 USF Magnolia Dr., MCB-CPT, Tampa, FL, 33612-9416, USA. mfradley@health.usf.edu.
Abstract
PURPOSE OF REVIEW: The anticoagulation strategies for various cardiac-specific pathologies including atrial fibrillation are changing. Applying these strategies in patients with concomitant active cancer requires additional considerations. Here, we review the most recent changes in the anticoagulation management of common cardiac diseases and their application in cancer patients. RECENT FINDINGS: There are a range of indications for therapeutic anticoagulation in cancer patients including venous thromboembolism (VTE), atrial fibrillation/flutter (AF/AFL), prosthetic heart valves, and intracardiac thrombi. Certain cancer therapeutics such as ibrutinib and anthracycline chemotherapy increase the risk of developing AF/AFL and pose unique challenges in anticoagulation management. Anticoagulation decisions for AF/AFL often utilize the CHADS2 or the CHA2DS2-VASc score with annualized stroke risk; however, these risk stratification models may be inadequate in cancer patients. Cancer type, stage, prognosis, and bleeding risk are all relevant when considering whether to initiate therapeutic anticoagulation. Moreover, thrombocytopenia may limit the ability to provide anticoagulation. Subsequent analyses of direct oral anticoagulants (DOACs) show fewer bleeding complications and thromboembolic events compared to warfarin in AF/AFL with apixaban and edoxaban particularly promising in this population for VTE, pulmonary embolism, and AF/AFL. There is a lack of data regarding ablation therapy and left atrial occlusion devices in this population. There is a growing experience of DOACs for intracardiac thrombi. Warfarin is still appropriate for patients with prosthetic heart valves and left ventricular assist devices. Anticoagulation management in the cancer patient can be challenging. DOACs are often a safe alternative to warfarin in cancer-associated DVT/PE and AF/AFL, and may be preferable in certain circumstances. Other cardiac indications for anticoagulation including the presence of a mechanical heart valve remain unchanged and dependent on warfarin or heparin-based products.
PURPOSE OF REVIEW: The anticoagulation strategies for various cardiac-specific pathologies including atrial fibrillation are changing. Applying these strategies in patients with concomitant active cancer requires additional considerations. Here, we review the most recent changes in the anticoagulation management of common cardiac diseases and their application in cancerpatients. RECENT FINDINGS: There are a range of indications for therapeutic anticoagulation in cancerpatients including venous thromboembolism (VTE), atrial fibrillation/flutter (AF/AFL), prosthetic heart valves, and intracardiac thrombi. Certain cancer therapeutics such as ibrutinib and anthracycline chemotherapy increase the risk of developing AF/AFL and pose unique challenges in anticoagulation management. Anticoagulation decisions for AF/AFL often utilize the CHADS2 or the CHA2DS2-VASc score with annualized stroke risk; however, these risk stratification models may be inadequate in cancerpatients. Cancer type, stage, prognosis, and bleeding risk are all relevant when considering whether to initiate therapeutic anticoagulation. Moreover, thrombocytopenia may limit the ability to provide anticoagulation. Subsequent analyses of direct oral anticoagulants (DOACs) show fewer bleeding complications and thromboembolic events compared to warfarin in AF/AFL with apixaban and edoxaban particularly promising in this population for VTE, pulmonary embolism, and AF/AFL. There is a lack of data regarding ablation therapy and left atrial occlusion devices in this population. There is a growing experience of DOACs for intracardiac thrombi. Warfarin is still appropriate for patients with prosthetic heart valves and left ventricular assist devices. Anticoagulation management in the cancerpatient can be challenging. DOACs are often a safe alternative to warfarin in cancer-associated DVT/PE and AF/AFL, and may be preferable in certain circumstances. Other cardiac indications for anticoagulation including the presence of a mechanical heart valve remain unchanged and dependent on warfarin or heparin-based products.
Authors: M E Goldman; L A Pearce; R G Hart; M Zabalgoitia; R W Asinger; R Safford; J L Halperin Journal: J Am Soc Echocardiogr Date: 1999-12 Impact factor: 5.251
Authors: Russell D Hull; Graham F Pineo; Rollin F Brant; Andrew F Mah; Natasha Burke; Richard Dear; Turnly Wong; Roy Cook; Susan Solymoss; Man-Chiu Poon; Gary Raskob Journal: Am J Med Date: 2006-12 Impact factor: 4.965
Authors: A Natale; K H Newby; E Pisanó; F Leonelli; R Fanelli; D Potenza; S Beheiry; G Tomassoni Journal: J Am Coll Cardiol Date: 2000-06 Impact factor: 24.094
Authors: Agnes Y Y Lee; Frederick R Rickles; Jim A Julian; Michael Gent; Ross I Baker; Chris Bowden; Ajay K Kakkar; Martin Prins; Mark N Levine Journal: J Clin Oncol Date: 2005-02-07 Impact factor: 44.544
Authors: Agnes Y Y Lee; Mark N Levine; Ross I Baker; Chris Bowden; Ajay K Kakkar; Martin Prins; Frederick R Rickles; Jim A Julian; Susan Haley; Michael J Kovacs; Michael Gent Journal: N Engl J Med Date: 2003-07-10 Impact factor: 91.245
Authors: Avirup Guha; Anubhav Jain; Ankita Aggarwal; Amit K Dey; Sourbha Dani; Sarju Ganatra; Francis E Marchlinski; Daniel Addison; Michael G Fradley Journal: BMC Cardiovasc Disord Date: 2022-06-17 Impact factor: 2.174
Authors: Muzna Hussain; Rabel Misbah; Eoin Donnellan; Saqer Alkharabsheh; Yuan Hou; Feixiong Cheng; Michael Crookshanks; Chris J Watson; Andrew J Toth; Penny Houghtaling; Rohit Moudgil; G Thomas Budd; W H Wilson Tang; Deborah H Kwon; Wael Jaber; Brian Griffin; Mohamad Kanj; Patrick Collier Journal: Open Heart Date: 2020-11